development2.themmrf.orgMMRF - Multiple Myeloma Research Foundation

Multiple Myeloma Multiple Myeloma Diagnosis Prognosis Understanding survival statistics Treatment options Standard treatments Stem cell transplants Clinical trials and experimental therapies Supportive care Treatment guides Symptomsside effects Glossary Finding a Cure Finding a Cure Our achievements Our approach Our work Immunotherapy Myeloma Investment Fund The MMRF CureCloud ® CoMMpass ℠ Study Multiple Myeloma Research Consortium MyDRUG clinical trial Resources Resources Patient Navigation Center The Right Track Education programs Find a support group Financial assistance Myeloma Mentors Find a treatment center Clinical trial finder About About News, press and blogs Diversity, Equity and Inclusion Executive leadership Board of directors Honorary board Financials Get Involved Get Involved Participate in research Ways to donate Join an event Patient Navigator Patient Navigator Donate Our mission: cure multiple myeloma The Multiple Myeloma Research Foundation (MMRF) drives discoveries for new treatments, accelerates groundbreaking clinical trials and fuels the most robust data-driven initiatives in cancer research. Our goal is to find a cure for each and every patient diagnosed with multiple myeloma. The latest from The MMRF MMRF Blogs Dr. Elsey’s Fund to Cure Cancer –Year End Million Dollar Match Scientific/Research Publications Updates on Smoldering Multiple Myeloma and COVID-19 Vaccination Scientific/Research Publications The Latest Updates on Small Molecules for Relapsed / Refractory Multiple Myeloma Scientific/Research Publications Updates on Treatments for Patients With Newly Diagnosed Multiple Myeloma MMRF Blogs Advances for Patients With Relapsed / Refractory Multiple Myeloma: Immunotherapy MMRF Blogs Day 3 Highlights from the 2021 International Myeloma Workshop MMRF Blogs Day 2 Highlights from the 2021 International Myeloma Workshop MMRF Blogs Day 1 Highlights from the 2021 International Myeloma Workshop Accelerator Magazine Summer 2021 Accelerator COVID-19 and Multiple Myeloma While Secretary Powell was a patient himself and was vaccinated against COVID-19, the outcome of his situation should not deter other immunocompromised patients from working with their doctor to consider vaccination. Learn More Understanding multiple myeloma Discover more information about multiple myeloma, such as symptoms, side effects, treatment options and more. More about multiple myeloma What do I do now? One Get informed Talk to our trained professionals Talk to a myeloma expert at our Patient Navigation Center who can help you understand your diagnosis, provide support and answer questions. Let's talk Get important information you need Sign up to learn about clinical trials, treatment options and the latest news to help you make the right decisions. Sign up Two Find the right track for treatment The MMRF’s Right Track program puts you on the path to the best results for you. THE RIGHT TRACK ™ Right Team Access experts and centers that have extensive experience treating multiple myeloma Right Tests Get the information, tests and precise diagnoses to make the right treatment decisions Right Treatment ­ Work with your team to decide on the best treatment plan and identify clinical trials that are right for you Get on the right track Three Join our study to find personalized treatments Participate in the MMRF CureCloud The MMRF CureCloud® is a research study that includes the first at-home genomic testing program. This comprehensive data hub of clinical and genomic information can help researchers, clinicians and patients make smarter treatment decisions. Join The MMRF CureCloud Unprecedented results The MMRF’s patient-centered approach is changing cancer research. We’re problem solvers and innovators. Over the years, we’ve found original and creative ways to speed research, fund initiatives and break through the institutional barriers that can slow progress. Our unrelenting focus is on helping every patient find the right treatment. Finding a cure $ 500 M raised for research 15 drugs brought to market 3 x increase in life expectancy Working with the community to advance this extraordinary progress in myeloma has been the greatest honor of my life. Kathy Giusti, Founder The MMRF Get involved Upcoming 12 September Team for Cures MMRF Virtual 5K Walk/Run Programs Team for Cures Be part of our Team for Cures program, which brings together the myeloma community and supporters to raise funds for research and celebrate progress. Take part in our 5K Walk/Run program , one of our Endurance Events or host your own event via the Independent Events program . View events Create Your Own Event The MMRF makes it easy to turn your passion into purpose and help to accelerate a cure for all multiple myeloma patients. Whether you’re hosting your own private cooking class, creating a golf tournament, or celebrating a milestone event, create your own independent event today - we can help you fundraise your way! View events Get the latest myeloma news and updates Knowledge is power. Sign up today and we’ll help you stay informed. Sign up We value your privacy . 383 Main Avenue, 5th Floor Norwalk, CT 06851 1-203-229-0464 Contact Us Careers Our sponsors Research grants Leadership Outreach Privacy policy Donor privacy policy Terms of use How we collaborate The MMRF is a registered 501(c)(3) non-profit. Tax ID: 06-1504413 For donations please mail to: P.O. Box 414238 Boston, MA 02241-4238 © 2021, Multiple Myeloma Research Foundation, Inc. Donate Search for: Patient Navigator Donate Get the latest myeloma news and updates Knowledge is power. Sign up today and we'll help you stay informed. Sign up We value your privacy . International Data Transfers Adequacy Decision: We may transfer your Personal Data to Switzerland and other countries which the European Commission has approved as providing adequate protection to personal data. A list of these countries can be found here: Standard Contractual Clauses: The European Commission has adopted standard data protection clauses, which provide safeguards for personal data transferred outside of the EEA. We sometimes use Standard Contractual Clauses when transferring Personal Data from a country in the EEA to a country outside the EEA. You can request a copy of our Standard Contractual Clauses by contacting us as set forth in the Contact Us section below. With your consent: In respect of certain cross-border personal data transfers, such as in research studies that you provide consent to enter, we will obtain your consent to transfer your Personal Data outside the EEA after first informing you about the possible risks of such a transfer. By contract: We will transfer your Personal Data outside the EEA if the transfer is necessary to the performance of a contract between you and MMRF, or if the transfer is necessary to the performance of a contract between MMRF and a third party, and the contract was entered into in your interest. In addition, we may transfer your Personal Data outside the EEA if the transfer is necessary to establish, exercise or defend legal claims or to protect your vital interests. Measuring your prognosis Test Indication Values Indicating a More Favorable Prognosis Beta 2-microglobulin (β2-microglobulin or β2-M) Higher levels reflect more extensive disease and poor kidney function 3 mg/mL Albumin level Higher levels may indicate better prognosis ≥3.5 g/dL Lactate dehydrogenase (LDH) level Higher levels indicate more extensive disease Age ≤60yrs.: 100-190 U/L Age 60yrs.: 110-210 U/L Albumin level Higher levels may indicate better prognosis ≥3.5 g/dL FreeliteTM serum free light chain assay Abnormal results may indicate poor prognosis (also indicates risk of progression of MGUS or asymptomatic myeloma or symptomatic myeloma Free light chain ratio MGUS: 0.26-1.65 Asymptomatic myeloma:0.125-8.0 Symptomatic myeloma:0.03-32 Revised International Staging System for multiple myeloma Stage Criteria I ß2-M3.5mg/L and...